Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
Key facts today
The Trump administration announced a pilot program to include weight loss drugs like Mounjaro in Medicare and Medicaid, starting in 2026 and 2027, which may boost Eli Lilly's market access.
300 ARS
9.70 T ARS
41.24 T ARS
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFTQS8
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
LLY Ready to Break Out? Here's What the Chart Tells Us🚨 LLY Ready to Break Out? Here's What the Chart Tells Us
Back in November 2024, we shared an idea warning that Eli Lilly (LLY) was facing some serious headwinds.
Since then, the market has confirmed it, NYSE:LLY has spent nearly a year moving sideways , showing little strength to push th
LLY Is Overbought ---$615 Put Play**💊 LLY WEEKLY TRADE IDEA — BEARISH PRESSURE BUILDING**
📉 **Sentiment:** Strong bearish lean (70% confidence) — low RSI, high volume distribution.
📊 **Institutional Flow:** 1.7x weekly volume, puts stacking near key strikes.
⚠ **Risk:** Gamma risk + oversold → expect high volatility.
**🛠 Setup:**
Rare Discount Below $700LLY’s sell-off today is driven by underwhelming data from its new oral GLP‑1 drug—but it came on the heels of an otherwise stellar earnings report and outlook upgrade. If you believe in Lilly’s leadership in obesity and diabetes treatments, its strong cash flows, and long-term drug development pipel
Conservative Bullish Case for Eli Lilly: A Pharmaceutical LeaderEli Lilly (LLY) is currently trading at $812.95, having recently shown strength by climbing from the mid-$700s to over $800 in the past month. The stock has established a key support zone in the $760-780 range while testing resistance around the current price level.
Fundamental Strength
LLY's rece
LLY - Earnings upcoming, recent news makes this appealing📈 LLY — Eli Lilly & Co.
Ticker: LLY | Sector: Biotech / Pharmaceuticals
Date: July 26, 2025
Current Price: ~$813
Resistance Zone: $825
Support Zone: $740–$750
🧪 Recent Drug News
1. EMA Backs Alzheimer’s Drug Donanemab (Kisunla)
The European Medicines Agency’s advisory committee has issued a positiv
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS238628644
ELI LILLY 21/43Yield to maturity
7.69%
Maturity date
Sep 14, 2043
US532457BY3
ELI LILLY 20/50Yield to maturity
7.06%
Maturity date
May 15, 2050
US532457BZ0
ELI LILLY 20/60Yield to maturity
6.94%
Maturity date
Sep 15, 2060
US532457BU1
ELI LILLY 19/59Yield to maturity
6.13%
Maturity date
Mar 15, 2059
US532457BT4
ELI LILLY 19/49Yield to maturity
6.06%
Maturity date
Mar 15, 2049
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
5.95%
Maturity date
Jun 15, 2044
LLY4217068
Eli Lilly and Company 3.7% 01-MAR-2045Yield to maturity
5.88%
Maturity date
Mar 1, 2045
LLY4492882
Eli Lilly and Company 3.95% 15-MAY-2047Yield to maturity
5.86%
Maturity date
May 15, 2047
US532457BS6
ELI LILLY 19/39Yield to maturity
5.81%
Maturity date
Mar 15, 2039
LLY5547405
Eli Lilly and Company 4.95% 27-FEB-2063Yield to maturity
5.78%
Maturity date
Feb 27, 2063
LLY5750032
Eli Lilly and Company 5.1% 09-FEB-2064Yield to maturity
5.74%
Maturity date
Feb 9, 2064
See all LLY bonds